Evidence map›Paper›PMID 30120496›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2018

Age-corrected hearing loss after chemoradiation in cervical cancer patients.

S Marnitz, L Schermeyer, S Dommerich, C Köhler, H Olze, V Budach, P Martus

Abstract read
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Effects of Cholesterol Modulation on Cisplatin-Induced Hearing Loss.bioRxiv : the preprint server for biology · 2025
    Article
  2. Early-Phase Trial of IAP Antagonist Tolinapant and Definitive Radiation in Cisplatin-Ineligible Patients with Advanced Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Statins: a repurposed drug to fight cancer.Journal of experimental & clinical cancer research : CR · 2021
    Review
  8. Article
  9. Observational
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

S MarnitzMedical Faculty, Department of Radiation Oncology, CyberKnife Center, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. simone.marnitz-schulze@uk-koeln.de.
L SchermeyerDepartment of Radiation Oncology, Charité University Clinic, Berlin, Germany.
S DommerichDepartment of Otolaryngology, Head and Neck Surgery, Charité University Clinic, Berlin, Germany.
C KöhlerDepartment of Gynecologic Oncology, Asklepios Clinic Hamburg, Hamburg, Germany.
H OlzeDepartment of Otolaryngology, Head and Neck Surgery, Charité University Clinic, Berlin, Germany.
V BudachDepartment of Radiation Oncology, Charité University Clinic, Berlin, Germany.
P MartusInstitute of Clinical Epidemiology and Applied Biosta5s5cs, Eberhard-Karls-University Tübingen, Tübingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to evaluate subjective and objective hearing loss in cervical cancer patients after chemoradiation with cisplatin (mono). PATIENTS AND

methodsA total of 51 cervical cancer patients with indication for chemoradiation were included. Pure tone and impedance audiometry were performed before and after chemoradiation. Hearing loss was scaled according to ASHA criteria. Subjective hearing was assessed with the Oldenburger Sentence Test. To consider age-dependent changes, hearing loss was corrected for age and the time interval between measurements.

resultsMedian age at diagnosis was 46 years, 46% were active/former smokers (n = 24), 28 (54%) patients were never-smokers. Median total weekly cisplatin dose was 70 ± 14.2 mg. Cumulative doses of cisplatin during chemoradiation ranged between 115.2 and 400 mg cisplatin (mean 336.1 mg, median 342 ± 52.7 mg). The median interval between last chemotherapy and second audiometry was 320 ± 538 days (35-2262 days). Changes in hearing threshold ≥20 dB were experienced by 32/52 patients (62%) following chemoradiation, 55% of them for frequencies ≥6000 Hz. No statistically significant hearing loss remained after chemoradiation upon correction for age and time interval. Patients >40 years had a higher risk of hearing loss than younger patients. Objective data on hearing function did not correlate with subjective hearing loss and did not impair daily activity in any patient.

conclusionChemoradiation with cumulative cisplatin doses up to 400 mg did not lead to significant impairment of objective or subjective hearing. For cervical cancer patients undergoing chemoradiation, standard audiometry is not indicated.

Indexed as

Acoustic Impedance TestsAdultAge FactorsAudiometry, Pure-ToneAuditory ThresholdChemoradiotherapyCisplatinCombined Modality TherapyDose-Response Relationship, DrugFemaleHearing LossHumansMiddle AgedRisk FactorsSpeech Discrimination TestsUterine Cervical NeoplasmsCisplatinAudiometryCisplatinHearing loss, sensorineuralQuality of lifeRisk factors

Identifiers

PMID30120496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.